key: cord-0700191-8rekaw3c
authors: Chen, Hsu-Yu; Huang, Chun; Tian, Lu; Huang, Xiaoli; Zhang, Chennan; Llewellyn, George N.; Rogers, Geoffrey L.; Andresen, Kevin; O’Gorman, Maurice R.G.; Chen, Ya-Wen; Cannon, Paula M.
title: Cytoplasmic tail truncation of SARS-CoV-2 Spike protein enhances titer of pseudotyped vectors but masks the effect of the D614G mutation
date: 2021-06-22
journal: bioRxiv
DOI: 10.1101/2021.06.21.449352
sha: f51b41b3e4129f8b3405f5f882fd3dfad11db97d
doc_id: 700191
cord_uid: 8rekaw3c

The high pathogenicity of SARS-CoV-2 requires it to be handled under biosafety level 3 conditions. Consequently, Spike protein pseudotyped vectors are a useful tool to study viral entry and its inhibition, with retroviral, lentiviral (LV) and vesicular stomatitis virus (VSV) vectors the most commonly used systems. Methods to increase the titer of such vectors commonly include concentration by ultracentrifugation and truncation of the Spike protein cytoplasmic tail. However, limited studies have examined whether such a modification also impacts the protein’s function. Here, we optimized concentration methods for SARS-CoV-2 Spike pseudotyped VSV vectors, finding that tangential flow filtration produced vectors with more consistent titers than ultracentrifugation. We also examined the impact of Spike tail truncation on transduction of various cell types and sensitivity to convalescent serum neutralization. We found that tail truncation increased Spike incorporation into both LV and VSV vectors and resulted in enhanced titers, but had no impact on sensitivity to convalescent serum inhibition. In addition, we analyzed the effect of the D614G mutation, which became a dominant SARS-CoV-2 variant early in the pandemic. Our studies revealed that, similar to the tail truncation, D614G independently increases Spike incorporation and vector titers, but that this effect is masked by also including the cytoplasmic tail truncation. Therefore, the use of full-length Spike protein, combined with tangential flow filtration, is recommended as a method to generate high titer pseudotyped vectors that retain native Spike protein functions. IMPORTANCE Pseudotyped viral vectors are useful tools to study the properties of viral fusion proteins, especially those from highly pathogenic viruses. The Spike protein of SARS-CoV-2 has been investigated using pseudotyped lentiviral and VSV vector systems, where truncation of its cytoplasmic tail is commonly used to enhance Spike incorporation into vectors and to increase the titers of the resulting vectors. However, our studies have shown that such effects can also mask the phenotype of the D614G mutation in the ectodomain of the protein, which was a dominant variant early in the COVID-19 pandemic. To better ensure the authenticity of Spike protein phenotypes when using pseudotyped vectors, we therefore recommend using full-length Spike proteins, combined with tangential flow filtration methods of concentration, if higher titer vectors are required.

8 Although this method shortened the overall process compared to a typical protocol that 147 first seeds the cells in a tissue culture plate for 24 hours before incubation with vectors, it 148 resulted in significantly lower transduction rates (Fig. 2B ). Examination of cell surface 149 ACE2 levels by flow cytometry revealed that newly trypsinized cells had 1.5-fold lower 150

ACE2 levels compared to cells allowed to recover for 6 hours post-trypsinization (Fig. 2C) , 151

suggesting the reason for the lower titers. 152

Finally, we tested the susceptibility of a 3D lung bud organoid model to SΔ18 VSV 153 pseudovectors carrying a GFP reporter. Compared to cell lines, lung organoids provide 154 more physiologically relevant models of virus infection and have been used to identify 155 candidate COVID-19 therapeutics (29). SΔ18 pseudotyped VSV-GFP vectors were able 156 to efficiently transduce the cells, with GFP expression observed throughout the organoid 157 by 24 hours (Fig. 2D) . To identify an optimal method for concentration of Spike protein pseudovectors 162 suitable for a research laboratory, we compared ultracentrifugation through a 20% w/v 163 sucrose cushion with tangential flow filtration (TFF). Ultracentrifugation is limited by the 164 capacity of a rotor, for example SW28 rotors have a maximum capacity of ~230 ml of 165 vector supernatant per 2 hours run. In contrast, TFF can process much larger volume 166 (65, 66) and a single TFF filter with 1000 cm 2 surface area can process up to 3000 ml in 167 9 VSV-G pseudotyped LV vectors produced by TFF are reported to have a higher recovery 169 rate than when prepared by ultracentrifugation (66) . 170

To compare these approaches, 100 ml of SΔ18 pseudotyped VSV-Luc vector 171 supernatants were subjected to either ultracentrifugation (Ultra) or TFF and concentrated 172 into a 8ml final stock (12x, v/v) . Vector genome copies in the unconcentrated and 12x 173 concentrated vector stocks were measured by ddPCR, which revealed slightly better 174 recovery rates following TFF (~70%) compared to ultracentrifugation (~60%) (Fig. 3A and 175 3B). At the same time, the transduction efficiencies of the three vector stocks were 176 measured on HeLa-ACE2 cells, using serially diluted vectors (1:5 to 1:450 dilutions) (Fig. 177 3C). At the higher dilution points, both 12x Ultra and 12x TFF vector preparations 178 produced about a 10-fold higher luciferase signal compared to the unconcentrated 179 vectors. Interestingly, at the lower dilutions (1:5 and 1:15), the 12x Ultra vector stock 180 showed no enhancement over unconcentrated vectors, while the 12x TFF vector stocks 181 retained their 10-fold higher transduction rates. This observation is suggestive of the 182 presence of an inhibitory factor that is concentrated during ultracentrifugation but was not 183 retained following TFF. 184

In summary, we found that TFF facilitates large-scale processing of vector stocks, 185 with similar genomic copy number recovery rates as the more typical ultracentrifugation 186 method. More importantly, TFF results in vector stocks that retain a more consistent titer 187 throughout a broader range of different dilutions than those produced by 188 ultracentrifugation. 189 190 191

We used the VSV pseudovirus system to examine the impact of the D614G 193 mutation of Spike protein. This mutation was first detected in China and Germany in late 194 January and became the dominant circulating variant of SARS-CoV-2 globally by April 195 2020 (34) . The mutation has functional consequences for the virus, resulting in higher 196 viral loads in the upper respiratory tract (34, 67) . In vitro studies with SARS-CoV-2 197 revealed that the D614G mutation enhanced replication on human lung epithelial cells 198 and primary airway tissue (41), and increased replication or transmissibility in human 199 ACE2 transgenic mice and hamster models (41, 68, 69) . Effects were also observed using 200

Spike protein pseudoviruses, where the D614G mutation was reported to enhance Spike 201 incorporation into vector particles, despite minimal or no effect on Spike expression in 202 vector-producing cells (43, 70) , and to increase transduction rates on various cell lines 203 (30, 32, 34, 37, 43, 63, 71) . 204

Since we had noted that the cytoplasmic tail truncation of Spike protein also 205 increased incorporation rates and transduction efficiencies (Fig. 1) , we next examined the 206 impact of the D614G mutation in the context of both full-length and truncated Spike 207 proteins. For the full-length Spike protein, we observed up to 18-fold higher transduction 208 rates for the G614 variant on HeLa-ACE2 cells, with less striking effects on the other cell 209 lines we tested. In contrast, transduction rates for the variants in the SΔ18 backbone 210 showed minimal to no differences across the range of cell types tested (Fig. 4A ). The 211 discrepancy between the behavior of the full-length S and SΔ18 vectors occurred despite 212 similar genome copy numbers (Fig. 4B) , ruling out an effect on vector production. We 213 also observed no differences in cell surface expression levels of Spike when comparing 214

Pseudotyped vectors are a useful system to study the entry glycoproteins from 239 highly pathogenic viruses such as SARS-CoV-2, as they remove the need for BSL-3 240 laboratory conditions. We confirmed that the SARS-CoV-2 Spike protein was able to 241 pseudotype both LV and VSV vectors, and determined that the combination of using a 242 conditional VSV vector and a luciferase reporter gene had the advantage of allowing titers 243 to be read at 16 hours post-transduction. Such Spike pseudotyped VSV vectors 244 supported entry into a variety of mammalian cell types, including lung organoid systems, 245 making them a useful system with which to study SARS-CoV-2 entry under standard 246 laboratory conditions. 247

Optimization of pseudotyped vectors includes selection of an appropriate 248 concentration method, such as centrifugation, PEG precipitation or ultrafiltration. For VSV 249 pseudovectors, we found that concentration by TFF produced vector stocks with higher 250 recovery rates and more consistent titers throughout a dilution series than those produced 251 by ultracentrifugation. TFF also has the advantage of providing a partial purification due 252 to the selective loss of potential contaminants below the cut-off value of the filter, and 253 provides a larger processing capacity than ultracentrifugation. As a result, TFF is 254 frequently used to facilitate large-scale vector production, including for clinical use (65, 255 66, 72) . In our own experience, 3L of supernatant can be concentrated down to 50ml in 256 2 hours. 257

Since pseudovector titers can be impacted by incompatibilities between a viral 258 fusion protein and the heterologous viral particle (45) (46) (47) (48) (49) (50) , an additional strategy to 259 enhance vector titers has been to truncate the fusion protein's cytoplasmic tail. We found 260 13 that this approach increased the titers of Spike protein pseudovectors based on both LV 261 and VSV, in agreement with previous reports (24, (59) (60) (61) (62) (63) . Furthermore, as others have 262 also noted (59, 62), the enhanced vector titers correlated with increased levels of Spike 263 protein incorporation that were not simply the result of higher levels of cell surface 264 expression following tail truncation, and tail truncation has also been reported to enhance 265 the fusogenicity of Spike (59, 62). Together, this suggests that truncation of the 266 cytoplasmic could also alter the conformation or function of the protein's ectodomain, as 267 has been reported for viral fusion proteins in HIV (57) Our comparison of techniques to enhance vector titers also identified an area for 272 caution; although cytoplasmic tail truncation enhanced pseudovector titers, they can also 273 have unintended functional consequences. Specifically, we found that the impact of the 274 D614G mutation on Spike protein incorporation and vector titer was obscured by the 275 cytoplasmic tail truncation. A similar lack of effect of the D614G mutation on titer was also 276 reported in another study using a 21 amino acid deletion of the Spike protein cytoplasmic 277 tail in VSV pseudovectors (62). These findings suggest that tail-truncated Spike proteins 278 should be used with caution for studies analyzing the impact of Spike mutations, or to test 279 potential therapeutics targeting SARS-CoV-2 entry. 280

The mechanism for enhanced incorporation and/or titer by D614G is not entirely 281 understood but structural analyses have suggested that it could impact Spike protein 282 structure and stability, both within and between Spike monomers. For example, it has 283 been suggested that a glycine at this location could strengthen the association between 284 the S1/S2 subunits through an impact on the epistructure that decreases the 285 intramolecular wrapping in the S1 subunit but promotes intermolecular wrapping between 286 S1 and S2 (73). In an alternative model, the D614G mutation could alter the structure 287 and/or stability of the Spike trimer by abrogating the hydrogen bond connecting D614 in 288 the S1 subunit of one monomer with T859 in the S2 subunit of a neighboring monomer 289 (34). These alterations were hypothesized to result in a greater tendency of the G614 290 monomers to form stable trimers which, in turn, could facilitate their incorporation into 291 virions. As evidence, a mixture of equal amounts of D614 and G614 Spike variants 292 expressed in vector-producing cells resulted in a higher level of G614 proteins in the 293 incorporated Spike trimers (70). 294

Finally, we also used the VSV pseudovectors to evaluate the impact of the D614G 295 mutation on infectivity of different cell types and sensitivity to antibody neutralization. 296

Consistent with previous findings using pseudoviruses (32-34, 37, 43, 44) or SARS-CoV-297 2 virions (41, 68), we found that the G614 variant exhibited enhanced transduction of 298 various cell lines when compared to the D614 variant, and that this correlated with 299 increased Spike incorporation into the VSV particles (43, 70). As previously noted, these 300 effects were significantly abrogated when tail truncated variants were used, consistent 301

with an upper limit for the enhancement of Spike incorporation. 302

In contrast, the serum neutralization studies revealed no differences in sensitivity 303

for either residue at position 614, and in either of the cytoplasmic tail configurations. This 304 is in agreement with the majority of reports testing the impact of the D614G mutation with 305 full-length Spike pseudovectors or SARS-CoV-2 virus against human convalescent 306 serum (30, 34, 43, 68) , serum from convalescent animals (41), or vaccinated human or 307 animals (44, 68, 74) . 308

In summary, we found that although cytoplasmic tail truncations enhance SARS-309

CoV-2 Spike protein incorporation into both LV and VSV vectors, and enhance the titers 310 of unconcentrated vectors, they can also mask the phenotype of the D614G mutation. For larger scale production, quantities were adjusted to seed 3x10 7 cells in 500cm 2 345 plates, transfection with 124.5 μg of Spike expression plasmid and infection by 1.7x10 9 346 vector genomes of VSVΔG particles per 500cm 2 plate. To propagate VSVΔG particles, 347 the same protocol was followed but replacing the Spike expression plasmid with the same 348 quantity of a VSV G expression plasmid, and no PBS washes were performed after 349 infection by VSVΔG. System (Bio-Rad). Membranes were blocked with 5% milk in PBST buffer (PBS plus 0.1% 441 of Tween®20). The S1 subunit of Spike was detected using SARS-CoV-2 (COVID-19) 442

Spike S1 antibody at 1:1000 (Prosci, Cat.# 9083); the S2 subunit was detected using 

A pneumonia outbreak associated with a new 501 coronavirus of probable bat origin

Coronavirus Resource Center

A rapid review of recent advances in diagnosis, treatment and vaccination 506 for COVID-19

Current status on the development of 560 pseudoviruses for enveloped viruses

Construction and applications of SARS-CoV-2 562 pseudoviruses : a mini review

A Replication-Competent Vesicular Stomatitis 567

Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition

Characterization of spike 571 glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with 572 SARS-CoV

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked 578 by a Clinically Proven Protease Inhibitor

Establishment and 581 validation of a pseudovirus neutralization assay for SARS-CoV-2

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor

Binding Domain that Escape Antibody Recognition

Role of IgM and IgA Antibodies to the Neutralization of SARS-CoV-2. 614 medRxiv

Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody 619

Activity in Recovered COVID19 Patients

High affinity modified ACE2 receptors prevent SARS-CoV-2 infection

Identification of SARS-CoV-2 Inhibitors using Lung 629 and Colonic Organoids

SARS-CoV-2 D614G spike mutation 632 increases entry efficiency with enhanced ACE2-binding affinity

Neutralization of SARS-CoV-2 636

1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

The spike d614g mutation increases sars-cov-2 infection of multiple human 640 cell types

Delineate a pH-Dependent Switch 4 that Mediates Endosomal Positioning of 646 SARS-CoV-2 Spike Receptor-Binding Domains

Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the 655 COVID-19 Virus

Escape from 660 neutralizing antibodies by SARS-CoV-2 spike protein variants

Antibody resistance of SARS-CoV-2 665 variants B.1.351 and B.1.1.7

D614G mutation of SARS-CoV-2 spike protein 668 enhances viral infectivity

Molecular determinants 672 and mechanism for antibody cocktail preventing SARS-CoV-2 escape

2021. mRNA vaccine-elicited antibodies to SARS-680

CoV-2 and circulating variants

Moore 684 PL. 2021. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-685 19 donor plasma

Spike mutation D614G alters SARS-CoV-2 fitness

Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals 693 Constraints on Folding and ACE2 Binding

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and 697 infectivity

Increases SARS CoV-2 Susceptibility to Neutralization

Göttlinger 705

Truncation of the human immunodeficiency virus type 1 envelope 706 glycoprotein allows efficient pseudotyping of Moloney murine leukemia virus 707 particles and gene transfer into CD4+ cells

Sequences in the Cytoplasmic Tail of the 709

Gibbon Ape Leukemia Virus Envelope Protein That Prevent Its Incorporation into 710

Lentivirus Vectors

Targeted cell entry of lentiviral vectors

Receptor-Targeted Nipah Virus Glycoproteins Improve Cell-715

Type Selective Gene Delivery and Reveal a Preference for Membrane-Proximal 716

Characterization of a third generation 718 lentiviral vector pseudotyped with Nipah virus envelope proteins for endothelial cell 719 transduction

Truncation of the 721 human immunodeficiency virus-type-2 envelope glycoprotein allows efficient 722 pseudotyping of murine leukemia virus retrovital vector particles

Retroviruses Pseudotyped with the 726

Severe Acute Respiratory Syndrome Coronavirus Spike Protein Efficiently Infect 727

Cells Expressing Angiotensin-Converting Enzyme 2

Cytoplasmic Tail of Moloney Murine 729

Leukemia Virus Envelope Protein Influences the Conformation of the Extracellular 730

Domain: Implications for Mechanism of Action of the R Peptide

A functional henipavirus envelope glycoprotein 733 pseudotyped lentivirus assay system

Polybasic 735

KKR Motif in the Cytoplasmic Tail of Nipah Virus Fusion Protein Modulates 736

Membrane Fusion by Inside-Out Signaling

Truncation of the cytoplasmic domain of the simian 738 immunodeficiency virus envelope glycoprotein increases env incorporation into 739 particles and fusogenicity and infectivity

Measles Viruses with Altered Envelope 741

Protein Cytoplasmic Tails Gain Cell Fusion Competence

Seaman 743 HIV-1 envelope glycoprotein

Truncating the gp41 Cytoplasmic Tail of Simian Immunodeficiency Virus Decreases 747

Sensitivity to Neutralizing Antibodies without Increasing the Envelope Content of 748

Deletion of the SARS-CoV-2 Spike 751

Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays

Optimized Pseudotyping Conditions for the SARS-755

COV-2 Spike Glycoprotein

Measuring SARS-CoV-2 neutralizing antibody 760 activity using pseudotyped and chimeric viruses

SARS-CoV-2 Spike Alterations Enhance

Comprehensive and systemic optimization for 765 improving the yield of SARS-COV-2 spike pseudotyped virus

Optimization and 769 validation of the TZM-bl assay for standardized assessments of neutralizing 770 antibodies against HIV-1

Highly 772 efficient large-scale lentiviral vector concentration by tandem tangential flow 773 filtration

Upscaling of 775 lentiviral vector production by tangential flow filtration

SARS-CoV-2 viruses associated with lower viral loads in patient upper airways

D614G variant exhibits efficient replication ex vivo and transmission in vivo

SARS-CoV-2 spike D614G 791 change enhances replication and transmission

The SARS-CoV-2 Spike mutation D614G 793 increases entry fitness across a range of ACE2 levels, directly outcompetes the 794 wild type, and is preferentially incorporated into trimers

Structural and Functional Analysis of the D614G SARS-CoV-2 800

Transfusion independence 807 and HMGA2 activation after gene therapy of human β-thalassaemia

Structural Impact of Mutation D614G in SARS-CoV-2 Spike 810 Protein: Enhanced Infectivity and Therapeutic Opportunity

Experimental and 815 in silico evidence suggests vaccines are unlikely to be affected by D614G mutation 816 in SARS-CoV-2 spike protein

Transmission, infectivity, and antibody neutralization of an 825 emerging SARS-CoV-2 variant in California carrying a L452R spike protein 826 mutation

Generation of VSV pseudotypes using recombinant ΔG-VSV for 828 studies on virus entry, identification of entry inhibitors, and immune responses to 829 vaccines

A three-dimensional model of human lung 833 development and disease from pluripotent stem cells

A Cross-Sectional Study Examining the 835

variants on 293T vector-producing cells, measured by flow cytometry using anti-S1 or 886 anti-S2 antibodies at the time of vector harvest. Expression levels are reported as mean 887 fluorescence intensity (MFI). Control 293T cells were from "bald" vector production, which 888were not transfected with any glycoprotein but still infected by the VSVΔG particles.